Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2629 - The Role of FDG-PET/CT in Detecting Bone Marrow involvement in Diffuse Large B-Cell Lymphoma

Date

09 Sep 2017

Session

Poster display session

Topics

Lymphomas

Presenters

Ajaz Bulbul

Citation

Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373

Authors

A. Bulbul1, E.A. Mino1, S. Chouial1, A. Bautista1, A. Mustafa2, H. Abboud3, S. Rashad4, T. Braik1, K. Masoud1

Author affiliations

  • 1 Hematology/ Oncology, Kymera Independent Physicians, 88220 - Carlsbad/US
  • 2 Anesthesiology, Acharya Shri Chander College of Medical Sciences and Hospital, 180017 - Jammu/IN
  • 3 Medicine, Windsor University, 60449 - Monee/US
  • 4 Medicine, All Saints University of Medicine, 00109 - Roseau/DM
More

Resources

Abstract 2629

Background

The sensitivity and prognostic value of FDG-PET/CT in the staging of Diffuse Large B-Cell lymphoma (DLBCL) remain unclear. PET/CT provides a high level of accuracy for identifying focal skeletal marrow disease in Hodgkin's lymphoma (HL). Whether the omission of staging Bone Marrow Biopsy (BMB) would change treatment strategy of DLBCL is not known.

Methods

We retrospectively studied 114 patients with DLBCL from three rural community oncology practices in New Mexico between January 96- September 2016. Patients receiving BMB and PET/CT were included. Descriptive statistics and Chi-square methods were used to evaluate associations.

Results

Mean age at diagnosis was 66 years (23-92), 54% were males, 82% received RCHOP therapy. Out of 114 patients, 27 (23%) patients did not have a staging BM biopsy. The sensitivity of PET/CT scan was 73% and Specificity 87%. Positive predictive value (PPV) 50% and Negative predictive value (NPV) 95%. Patients with positive focal PET/CT were more likely (50% vs 5%), χ2 (1, N = 74) = 19.9, (p 

Conclusions

PET/CT is valuable as having a high negative predictive value for detection of focal marrow involvement in DLBCL. This may help avoid BMB, especially if clinically early stage disease. Cytopenia did not predict marrow involvement. The long-term prognostic value of PET/CT is similar to that obtained by a bone marrow biopsy.

Clinical trial identification

Legal entity responsible for the study

Kymera Independent Physicians

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.